EZZ and AUT launch research agreement, with two initial studies investigating NMN absorption properties and a potential immunity booster for HPV

September 29 08:32 2021

EZZ Life Science Holdings (ASX: EZZ) is pleased to announce a new research agreement, together with leading university, Auckland University of Technology (AUT). The three-year agreement will see two studies conducted with research outcomes expected to yield new, science-backed additions to the EZZ supplements range.

It sees AUT and EZZ commence a three-year research relationship to utilise AUT’s renowned expertise in the areas of molecular immunology and bioactive compounds. The studies are being undertaken by eminent AUT researchers, Professor Jun Lu and Professor Fabrice Merien, with EZZ providing the products and herbal materials necessary for the project at no cost to AUT.

The research project will be broken into two core studies: one designed to enhance EZZ’s current, popular Nicotinamide mononucleotide (NMN) dietary supplement product; and the other to investigate the potential use of natural extracts in stimulating the human body’s immune response to Human Papillomavirus – or HPV infection. Study 1 aims to improve the conversion and absorption efficiency of NMN, while Study 2 may assist in the development of supplements that may help to prevent or treat HPV.

Executive Director and Chief Executive Officer of EZZ, Fernando Rodriguez commented, “Products containing NMN are growing increasingly popular with consumers, given emerging scientific literature about their anti-ageing properties. Through the first study, we will look at how several commercial strains of NMN are absorbed, comparing the absorption efficiency of the various strains in the blood stream. We expect the results to help with extending our product range.

“In the second study, we will investigate the potential for natural extracts to enable stimulation of the human body’s immune response as a defence to HPV infection. In particular, in countries where it is difficult to access HPV vaccines, EZZ is expecting consumer demand for such a potential new product.”

Professor Fabrice Merien, AUT’s Head of Department Biomedicine Medical Diagnostics and Director AUT-Roche Diagnostics Laboratory who will lead study 1, added, “We are very pleased to be working with EZZ on this emerging and promising healthcare product. The purpose of this research is to increase the conversion and absorption of NMN and thereby increase its efficacy and effectiveness as a supplement.”

Professor Jun Lu, AUT’s Professor of Biomedical Science and Pharmacology who will lead study 2, commented, “HPV has a significant unmet medical need, with around 80% of people infected with the virus at some point in their lives, and as HPV is a major cause of number of cancers – namely cervical cancer, the fourth most common cancer among women globally . By conducting this research, we aim to find more ways to prevent or treat HPV.”

The studies are expected to take around three years to complete, with reportable milestones along the way.

Media Contact
Company Name: Mbsc.sd
Contact Person: John Su
Email: Send Email
Country: United States
Website: https://www.yshanpay.com